Reviewer's Comments. eNO has been shown in many studies to be a useful marker of inflammation among asthmatics, but this study demonstrated an association between atopy and eNO levels. It has been suggested that eNO may be a useful screening test for asthma, and perhaps some of these asymptomatic atopic patients are evolving asthmatics. Although eNO devices have received Food and Drug Administration approval, their cost has limited their use to research settings to date. Methods. Pregnant women were enrolled and questioned about their allergy history before delivery and were given serial questionnaires throughout their children's infancy and childhood. The authors prospectively identified 49 children with a history of reactions to peanuts. Twentythree children were then confirmed as being allergic to peanuts with skin testing and double-blind, placebo-controlled, food challenge. There were 2 control groups, including children with eczema in the first 6 months of life whose mothers also had eczema and 140 children without peanut allergy who were randomly selected from the cohort. Cord blood samples stored at birth were retrieved and analyzed for peanut-specific and total immunoglobulin E (IgE) for the children with peanut allergy. Retrospective data on maternal consumption of peanuts during pregnancy and lactation, family history of peanut allergy, and the use of specific lotions and creams (the interviewer was not aware of which products contained peanut oil) were then obtained.
ucts and peanut allergy, soy protein fractions have shown homology to major peanut proteins and cross-sensitization could result from exposure to a common T cell epitope.
Reviewers' Comments. With the increase in peanut allergy and other food allergies, elucidation of risk factors for prevention of sensitization offers new strategies to combat this food allergy epidemic. Allergic sensitization through the skin has also been proposed for the development of asthma and has been demonstrated in mouse models of atopic dermatitis. Additional studies are needed to determine whether topical peanut oil treatment is definitely a risk factor for peanut allergy; however, it seems prudent to avoid the topical use of peanut oil-containing products among children with atopic dermatitis. The finding of soy consumption being associated with peanut allergy may be attributable to the increased likelihood of food-allergic children receiving soy products, rather than a specific association with peanut allergy. Confirmation of this association is needed. Purpose of the Study. To determine whether subcutaneous administration of a humanized anti-immunoglobulin E (IgE) antibody, TNX-901, raises the threshold of sensitivity to peanuts among patients with peanut allergy.
Study Population. Eighty-four patients between 12 and 60 years of age, with a history of allergic reactions to peanuts, total IgE levels between 30 and 1000 IU/mL, positive skin prick tests for peanuts, and documented reactions with formal peanut challenge at the start of the study, were studied.
Methods. A randomized, double-blind, placebo-controlled, dose-range study was performed. During the screening process, peanut allergy was confirmed and the threshold for reactivity was determined with a doubleblind, placebo-controlled, oral food challenge with encapsulated peanut flour. Patients were subsequently randomized to receive subcutaneous injections of placebo or TNX-901 (150, 300, or 450 mg) at 4-week intervals, for a total of 4 doses. Two to 4 weeks after the final injection, a final peanut challenge was performed, to determine the threshold of reactivity to peanuts after the treatments. Serum samples were obtained at 4-week intervals, to monitor trough total IgE levels.
Results. From mean baseline thresholds of sensitivity of 178 to 436 mg of peanut flour in the various groups, the mean increases in the oral food challenge threshold were 710 mg in the placebo group, 913 mg in the group given 150 mg of TNX-901, 1650 mg in the group given 300 mg of TNX-901, and 2627 mg in the group given 450 mg of TNX-901 (P Ͻ .001 for comparison of the 450-mg dose with placebo; P Ͻ .001 for trend with increasing dose). Patients who received 450 mg had a mean threshold of reactivity of 2805 mg of peanut protein (equivalent to ϳ9 peanuts), compared with 178 mg (equivalent to one half of a peanut) before the injections.
Conclusions. Subcutaneous administration of TNX-901 increases the threshold of reactivity to peanuts in a dosedependent manner, which may translate into protection against most accidental ingestions of peanuts.
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